摘要
目的:观察止咳平喘十二味合剂治疗痰热壅肺型咳嗽变异性哮喘的疗效及安全性。方法:根据随机原则,将148例咳嗽变异性哮喘进行分组,两组各74例。对照组给予常规西药治疗,观察组西药联合止咳平喘十二味合剂进行治疗,均治疗21 d。治疗后,比较两组患者在疗效、症状改善、肺功能、血清相关因子变化方面的差异性,并对两组方案的安全性进行评价。结果:观察组总有效率达94. 6%,明显高于对照组的79. 7%,组间比较有统计学意义(χ^2=7. 306,P <0. 05)。两组咳嗽症状均得以控制,在缓解时间上,观察组起效的时间明显较对照组快(P <0. 05),咳嗽消失时间观察组也明显短于对照组(P <0. 05);半年内复发率上,观察组有3例(4. 05%)复发,明显较对照组11例(14. 86%)少(P <0. 05)。治疗后,两组患者肺功能指标FEV1%预计值、FEV1/FVC以及PEF%预计值均有明显改善(P <0. 05),观察组改善程度明显较对照组为优(P <0. 05)。两组血清相关因子EOS、Ig E和TNF-α治疗后均有明显改善(P <0. 05),且观察组3个指标均明显低于对照组,组间差异均有统计学意义(P <0. 05)。结论:止咳平喘十二味合剂可提高痰热壅肺型咳嗽变异性哮喘患者的治疗效果,加速症状改善、并改善患者肺功能和抑制血清炎性因子,用药安全。
Objective: To observe the curative effect and safety of cough variant asthma( CVA) belonging to phlegm-heat obstruction in Lung syndrome treated with Zhike Pingchuan Shierwei Mixture. Methods: 148 patients with CVA were divided into two groups,74 cases each. The treatment plan of the control group was conventional Western Medicine,the observation group was treated with Zhike Pingchuan Shierwei Mixture on the above basis,and all were treated for 21 days. After treatment,the differences in curative effect,symptom improvement,lung function,and serum-related factors were compared between the two groups,and the safety of the two groups was evaluated. Results: In terms of total effective rate,the observation group was as high as 94. 6%,which was significantly higher than that of the control group( 79. 7%). The results were statistically significant(χ^2= 7. 306,P < 0. 05). The symptoms of cough were controlled in both groups. In the time of remission,the time of onset in the observation group was significantly faster than that in the control group( P < 0. 05),the disappearance time of cough in the observation group was also shorter than that of control group( P < 0. 05);in the recurrence rate,there were 3 cases( 4. 05%) in the observation group,which was significantly less than that of the control group( 14. 9 %)( P < 0. 05). After the same course of treatment,the two groups had a significant improvement in the FEV1% predicted value,FEV1/FVC and PEF% predicted values( P < 0. 05). The improvement degree of the observation group was significantly higher than that of the control group( P < 0. 05).The serum related factors EOS,Ig E and TNF-α were significantly lowered after treatment( P < 0. 05),and the three indexes of observation group were significantly lower than those of the control group,the differences were statistically significant( P < 0. 05). Conclusion: Zhike Pingchuan Shierwei Mixture can improve the curative effect of CVA patients with phlegm-heat obstruction in Lung syndrome,accelerate the improvement of symptoms,improve the lung function and alleviate serum inflammation,and safe medication.
作者
洪儿
鲍翊君
陈希尔
陈玲
HONG Er;BAO Yijun;CHEN Xier;CHEN Ling(Respiratory Department, Ningbo Chinese Medicine Hospital Affiliated withZhejiang University of Chinese Medicine, Ningbo, Zhejiang 315000)
出处
《中国中医药科技》
CAS
2019年第5期655-657,708,共4页
Chinese Journal of Traditional Medical Science and Technology
基金
浙江省中医药科技计划项目(2018ZA110)
